Harmine
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329605

CAS#: 442-51-3

Description: Harmine, also known as telepathine, is a fluorescent harmala alkaloid belonging to the beta-carboline family of compounds. It occurs in a number of different plants, most notably the Middle Eastern plant harmal or Syrian rue (Peganum harmala) and the South American vine Banisteriopsis caapi (also known as "yage" or "ayahuasca"). Harmine reversibly inhibits monoamine oxidase A (MAO-A), an enzyme which breaks down monoamines, making it a RIMA. Harmine selectively binds to MAO-A but does not inhibit the variant MAO-B.


Price and Availability

Size
Price

50mg
USD 90
Size
Price

200mg
USD 150
Size
Price

1g
USD 250

Harmine, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 329605
Name: Harmine
CAS#: 442-51-3
Chemical Formula: C13H12N2O
Exact Mass: 212.095
Molecular Weight: 212.252
Elemental Analysis: C, 73.56; H, 5.70; N, 13.20; O, 7.54


Synonym: Harmine; telepathine; Yageine; Yajeine; Banisterine; Leucoharmine.

IUPAC/Chemical Name: 7-methoxy-1-methyl-9H-pyrido[3,4-b]-indole

InChi Key: BXNJHAXVSOCGBA-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H12N2O/c1-8-13-11(5-6-14-8)10-4-3-9(16-2)7-12(10)15-13/h3-7,15H,1-2H3

SMILES Code: CC1=NC=CC2=C1NC3=C2C=CC(OC)=C3


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Patel K, Gadewar M, Tripathi R, Prasad SK, Patel DK. A review on medicinal importance, pharmacological activity and bioanalytical aspects of beta-carboline alkaloid ''Harmine''. Asian Pac J Trop Biomed. 2012 Aug;2(8):660-4. doi: 10.1016/S2221-1691(12)60116-6. Review. PubMed PMID: 23569990; PubMed Central PMCID: PMC3609365.

2: Brierley DI, Davidson C. Developments in harmine pharmacology--implications for ayahuasca use and drug-dependence treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Dec 3;39(2):263-72. doi: 10.1016/j.pnpbp.2012.06.001. Review. PubMed PMID: 22691716.

3: Dos Santos RG, Osório FL, Crippa JA, Hallak JE. Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. Rev Bras Psiquiatr. 2016 Mar;38(1):65-72. doi: 10.1590/1516-4446-2015-1701. Review. PubMed PMID: 27111702.

4: Ott J. Pharmahuasca: human pharmacology of oral DMT plus harmine. J Psychoactive Drugs. 1999 Apr-Jun;31(2):171-7. Review. PubMed PMID: 10438001.

5: Louis ED, Zheng W. Beta-carboline alkaloids and essential tremor: exploring the environmental determinants of one of the most prevalent neurological diseases. ScientificWorldJournal. 2010 Sep 1;10:1783-94. doi: 10.1100/tsw.2010.159. Review. PubMed PMID: 20842322; PubMed Central PMCID: PMC3700397.

6: Dixon Clarke SE, Ramsay RR. Dietary inhibitors of monoamine oxidase A. J Neural Transm (Vienna). 2011 Jul;118(7):1031-41. doi: 10.1007/s00702-010-0537-x. Review. PubMed PMID: 21190052.

7: Saeki M, Egusa H. [Novel strategies for the development of anabolic agents for treatment of osteoporosis]. Nihon Yakurigaku Zasshi. 2014 Dec;144(6):277-80. Review. Japanese. PubMed PMID: 25492363.

8: Abbassi R, Johns TG, Kassiou M, Munoz L. DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications. Pharmacol Ther. 2015 Jul;151:87-98. doi: 10.1016/j.pharmthera.2015.03.004. Review. PubMed PMID: 25795597.

9: Pfau W, Skog K. Exposure to beta-carbolines norharman and harman. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Mar 25;802(1):115-26. Review. PubMed PMID: 15036003.

10: Robinson ES, Anderson NJ, Crosby J, Nutt DJ, Hudson AL. Endogenous beta-carbolines as clonidine-displacing substances. Ann N Y Acad Sci. 2003 Dec;1009:157-66. Review. PubMed PMID: 15028582.

11: Louis ED. Environmental epidemiology of essential tremor. Neuroepidemiology. 2008;31(3):139-49. doi: 10.1159/000151523. Review. PubMed PMID: 18716411; PubMed Central PMCID: PMC2683985.

12: Talhout R, Opperhuizen A, van Amsterdam JG. Role of acetaldehyde in tobacco smoke addiction. Eur Neuropsychopharmacol. 2007 Oct;17(10):627-36. Review. PubMed PMID: 17382522.

13: Moloudizargari M, Mikaili P, Aghajanshakeri S, Asghari MH, Shayegh J. Pharmacological and therapeutic effects of Peganum harmala and its main alkaloids. Pharmacogn Rev. 2013 Jul;7(14):199-212. doi: 10.4103/0973-7847.120524. Review. PubMed PMID: 24347928; PubMed Central PMCID: PMC3841998.

14: Sourkes TL. "Rational hope" in the early treatment of Parkinson's disease. Can J Physiol Pharmacol. 1999 Jun;77(6):375-82. Review. PubMed PMID: 10537223.

15: Lesch OM, Walter H. New 'state' markers for the detection of alcoholism. Alcohol Alcohol. 1996 Mar;31 Suppl 1:59-62. Review. PubMed PMID: 8737002.

16: Shirakawa J, Kulkarni RN. Novel factors modulating human β-cell proliferation. Diabetes Obes Metab. 2016 Sep;18 Suppl 1:71-7. doi: 10.1111/dom.12731. Review. PubMed PMID: 27615134; PubMed Central PMCID: PMC5021183.

17: de Meester C. Genotoxic potential of beta-carbolines: a review. Mutat Res. 1995 Oct;339(3):139-53. Review. PubMed PMID: 7491124.

18: Dos Santos RG, Balthazar FM, Bouso JC, Hallak JE. The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging. J Psychopharmacol. 2016 Dec;30(12):1230-1247. Review. PubMed PMID: 27287824.

19: Sanchez-Ramos JR. Banisterine and Parkinson's disease. Clin Neuropharmacol. 1991 Oct;14(5):391-402. Review. PubMed PMID: 1742748.

20: Longo VG, Massotti M. Effect of tremorigenic agents on the cerebellum: a review of biochemical and electrophysiological data. Int Rev Neurobiol. 1985;26:315-29. Review. PubMed PMID: 2991159.